Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 4/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR7 | P34969 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21178259 | 0.88 | HTR6 (0.34) | BRD4HTR6DRD2HTR2AHTR7 | |
| SCHEMBL21178193 | 0.87 | BRD4 (0.44) | RXFP1BRD4HTR6DRD2HTR2A | |
| SCHEMBL21178911 | 0.82 | RXFP1 (0.35) | RXFP1HTR6DRD2HTR2AHTR7 | |
| SCHEMBL21178218 | 0.82 | RXFP1 (0.36) | RXFP1HTR6DRD2HTR2AHTR7 | |
| SCHEMBL21178205 | 0.80 | CDK7 (0.42) | RXFP1HTR6DRD2HTR2AHTR7 | |
| SCHEMBL29699020 | 0.80 | CDK7 (0.42) | RXFP1HTR6DRD2HTR2AHTR7 | |
| SCHEMBL21179249 | 0.79 | CCNK (0.49) | — | |
| SCHEMBL24583126 | 0.79 | PIK3CA (0.41) | RXFP1HTR6DRD2EGFR | |
| SCHEMBL25593890 | 0.78 | HTR6 (0.50) | HTR6DRD2HTR2AHTR7EGFR | |
| SCHEMBL21188476 | 0.76 | BRD4 (0.46) | BRD4HTR6DRD2HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210379065-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2021-12-09 | — | — | US | disclosed |
| EP-3740207-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| WO-2019143719-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019143719-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | CDK7, CDK3, CCNK | RXFP1 3800/4885BRD4 554/4885HTR6 3385/4885 |
| US-20210379065-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNK | RXFP1 3800/4885BRD4 554/4885HTR6 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.